An assessment of pattern of adverse drug reactions of cardiovascular drugs in a tertiary care institute


  • Smita Y. Wankhede Department of Pharmacology, BJ Medical College, Pune, Maharashtra, India
  • Milind L. Pardeshi Department of Pharmacology, BJ Medical College, Pune, Maharashtra, India
  • Vishal V. Ghorpade Department of Pharmacology, BJ Medical College, Pune, Maharashtra, India
  • Balasaheb B. Ghongane Department of Pharmacology, BJ Medical College, Pune, Maharashtra, India



Adverse drug reaction, Cardiovascular drugs, Pharmacovigilance


Background: Cardiovascular disease is very prevalent in India. So, use of cardiovascular drugs is also more. So, it is very important to keep watch on adverse drug reactions. Aim of this study was to assess the pattern of adverse drug reactions (ADRs) reported with cardiovascular drugs in a tertiary care institute.

Methods: The study was carried out in medicine department of a tertiary care hospital over a period of one year. Each ADR was analysed for demographic data, causality, relationship between frequency of ADRs and the number of drugs used etc. In statistical analysis Microsoft excel 2013, SPSS software was used.

Results: A total of 136 patients, 58 (43%) men and 78 (57%) women, using cardiovascular medications reported ADRs during the entire study period. Total 168 ADRs were reported out of which, Amlodipine (causing headache and edema feet) was the most common drug with 51 (30.3%) ADR’s followed by Enalapril, Aspirin and Isosorbide Dinitrate with 37 (22%), 24 (14.2%), 23 (13.6%) ADRs respectively. Most common ADR was headache (due to amlodipine and Isosorbide di nitrate) affecting 38 (22.62%) cases followed by dry cough 37 (22.02%) cases, edema feet 36 (21.43%), gastritis 24 (14.29%) and 10 (5.95%) of nausea.

Conclusions: Monitoring ADRs in patients using cardiovascular drugs is a matter of importance since this class of medicines are mostly used as multidrug therapy and always prone for ADRs.

Author Biography

Balasaheb B. Ghongane, Department of Pharmacology, BJ Medical College, Pune, Maharashtra, India


Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics: a report from the American Heart Association. Circulation. 2014;29:322-8.

Krishnan MN. Coronary heart disease and risk factors in India - On the brink of an epidemic?. Indian Heart Journal. 2012;64:364-7.

WHO Media center. Fact sheet: cardiovascular diseases (CVDs), 2016. Available at: Accessed 27 October 2016.

Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.

Progress Collaborative Group. Randomized trial of a perindopril-based blood pressure- lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358:1033-41.

MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.

Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-38.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81-106.

LaPointe NM, Jollis JG. Medication errors in hospitalized cardiovascular patients. Arch Intern Med. 2003;163:1461-6.

Zaki SA. Adverse drug reactions and causality assessment scales. Lung India. 2011;28(2):152-3.

Sriram S, Ghasemi A, Ramaswamy R, Devi M, Balasuramanian R, Ravi TK, Sabzghabaee AM. Prevalence of adverse drug reaction at a private tertiary care hospital in south India. JRMS. 2011;16(1):16-25.

Kaur S, Kapoor V, Mahajan R, Lal M, Gupta S. Patterns of ADRs and Risk Factors Involved: Study in Cardiology Unit Of An Indian Tertiary Care Center. Int J Pharmacol. 2009;8:1.

Lesar TS, Lomaestro BM, Pohl H. Medication-prescribing errors in a teaching hospital: A nine years experience. Arch Intern Med. 1997;157:1569-76.

Gholami K. Ziaie S. Shalviri G. Adverse drug reactions induced by cardiovascular drugs in outpatients, pharmacy practice. 2008;6(1):51-5.

Prakash S. Pharmacovigilance in India. Indian J Pharmacol. 2007;39-123.

Pharmacovigilance Programme of India for Assuring Drug Safety 2004, Indian Pharmacopoeia Commission, Ghaziabad: Directorate General of Health Services, Central Drugs Standard Control Organization, Ministry of Health and Family Welfare. Available at: Accessed 5 September 2016.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.

Singhal R, Ahmed K, Santani DD. Reporting and monitoring of adverse drug reactions with cardiac drugs. Int Res J Pharm. 2011;2:116-9.

Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmaco epidemiol Drug Saf. 2010;19:889-94.

Sharminder K, Vinod K, Rajiv M, Mohan L, Seema G. Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease. Indian J Pharmacol. 2011;43:22-6.

Muthiah P, Sandhiya S, Melvin G, Ganesan S, Steven A, Ajith P, et al. Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs in a Tertiary Care Teaching Hospital. JCDR. 2015;9(11):1-4.

Davies DM. History and epidemiology. In: Davies DM. Textbook of adverse drug reactions. 1st ed. Oxford: Oxford University Press; 1977;7-10.

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-6.

Snezana M, Zoran B, Aleksandra K, Aneta B, Dragana P, Zoran T. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72(11):975-98.

Hughes SG. Prescribing for the elderly patients: Why do we need to exercise caution? Br J Clin Pharmacol. 1998;46:531-3.

Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharmaceutical Journal 2014;22:83-94.

Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.




How to Cite

Wankhede, S. Y., Pardeshi, M. L., Ghorpade, V. V., & Ghongane, B. B. (2018). An assessment of pattern of adverse drug reactions of cardiovascular drugs in a tertiary care institute. International Journal of Basic & Clinical Pharmacology, 7(2), 273–277.



Original Research Articles